Endometriosis: Sexual Dysfunction and Adaptation Strategies Among Couples (DYSEXTRIOSE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Gard
-
Nîmes Cedex 09, Gard, France, 30029
- Centre Hospitalier Universitaire de Nîmes
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The patient (and her partner) must have given his/her informed and signed consent
- The patient (and her partner) must be insured or beneficiary of a health insurance plan
- Couples for whom the woman has formerly undergone surgical treatment for endometriosis, and for the partner agrees to respond to questionnaires for this study
Exclusion Criteria:
- The patient (or her partner) is participating in another study
- The patient (or her partner) is in an exclusion period determined by a previous study
- The patient (or her partner) is under judicial protection, under tutorship or curatorship
- The patient (or her partner) refuses to sign the consent
- It is impossible to correctly inform the patient (or her partner)
- The patient is pregnant
- The patient is breastfeeding
- The patient was surgically treated for endometriosis, but was single.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
The study population
All patients included according to state inclusion and exclusion criteria.
|
All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Score for the SFQ questionnaire
Time Frame: Day 1
|
Score for the SFQ questionnaire; varies from 0 to 5.
|
Day 1
|
|
Score for the IIEF questionnaire
Time Frame: Day 1
|
Score for the IIEF questionnaire; varies from 0 to 75.
|
Day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Scores for each sub-domain of the SFQ questionnaire
Time Frame: Day 1
|
Scores for each sub-domain of the SFQ questionnaire; varies from 0 to 5.
|
Day 1
|
|
Scores for each sub-domain of the IIEF questionnaire
Time Frame: Day 1
|
Scores for each sub-domain of the IIEF questionnaire; varies from 0 to 30.
|
Day 1
|
|
Sexual treatment request (yes/no)
Time Frame: Day 1
|
Did the patients request treatment/help for sexual problems?
yes/no
|
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LOCAL/2011/SD-05
- 2011-A00564-37 (Other Identifier: RCB number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.